Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Raw Materials (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Raw Materials for 15 consecutive years, with $12.2 million as the latest value for Q4 2025.

  • Quarterly Raw Materials fell 20.28% to $12.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.2 million through Dec 2025, down 20.28% year-over-year, with the annual reading at $12.2 million for FY2025, 20.28% down from the prior year.
  • Raw Materials for Q4 2025 was $12.2 million at Harvard Bioscience, down from $13.5 million in the prior quarter.
  • The five-year high for Raw Materials was $19.2 million in Q2 2022, with the low at $12.2 million in Q4 2025.
  • Average Raw Materials over 5 years is $16.1 million, with a median of $15.6 million recorded in 2021.
  • The sharpest move saw Raw Materials soared 34.18% in 2021, then dropped 24.1% in 2025.
  • Over 5 years, Raw Materials stood at $18.5 million in 2021, then dropped by 5.89% to $17.4 million in 2022, then decreased by 11.65% to $15.4 million in 2023, then decreased by 0.9% to $15.3 million in 2024, then decreased by 20.28% to $12.2 million in 2025.
  • According to Business Quant data, Raw Materials over the past three periods came in at $12.2 million, $13.5 million, and $14.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.